Details

Last Funding Type

Post-IPO Equity

Last Funding Money Raised

$220.35M

Industries

Biotechnology,Health Care,Medical,Therapeutics

Founded date

Jan 1, 2015

Number Of Employee

101 - 250

Operating Status

Active

Stock Symbol

nyse:RCUS

Legal Name

Arcus Biosciences, Inc.

Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.

It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio.

Arcus was formed in 2015 in Hayward, California by Terry Rosen and Juan Jaen.